Article

B + L, Topcon co-promote surgical items in Japan

Bausch + Lomb Japan and Topcon Medical Japan have announced a collaboration to co-promote their ophthalmic surgical products in Japan, including introduction of a proprietary microsurgery platform (Stellaris PC Vision Enhancement System).

Tokyo-Bausch + Lomb (B + L) Japan and Topcon Medical Japan have announced a collaboration to co-promote their ophthalmic surgical products in Japan, including introduction of a proprietary microsurgery platform (Stellaris PC Vision Enhancement System).

The proprietary microsurgery platform has been approved by the Ministry of Health, Labor, and Welfare and is now available in Japan. The platform received regulatory approval in the United States and Europe in 2010.

Under the agreement, B + L Japan is responsible for importing product and Topcon Medical Japan is responsible for sales, maintenance, and service. The two companies share responsibility for promotional activities.

“The launch of [the proprietary microsurgery platform] reaffirms B + L’s commitment to introducing innovative products to the Japanese market,” said Hideyuki Ashikaga, president, B + L Japan. “We anticipate that the combination of Topcon’s sales strength and service organization with B + L’s technology will advance the standards of eye care as the aging of Japan’s population continues.”

“This partnership with B + L is an excellent opportunity for Topcon Medical Japan to enhance our product offerings to our customers significantly,” said Hiroshi Fukuzawa, eye-care business unit director, executive managing director, and operating officer, Topcon Corp. “[The proprietary microsurgery platform] is a next-generation product that will evolve the surgical landscape in Japan by providing the most advanced technology for both vitreoretinal and cataract surgery in a single system. With a full-scale entry into the vitreoretinal and cataract surgery systems, we expect sales synergies with our already existing optical coherence tomography, operation microscope, ophthalmic laser, and our other products.”

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.